The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant
about
Characterization of HIV-1 envelopes in acutely and chronically infected injection drug usersSynergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones.Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clonesAntibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection.Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicidesHeterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures.Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics.Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
P2860
Q34620235-7FFEEC58-B765-4F66-9255-361513630231Q34762224-0BFBFE71-620B-4DA8-BC24-E9E23AEB59F6Q36532973-4C3F435C-BC40-4249-BE3A-105299491B90Q36763288-3DD9A97C-236C-44DE-BB8F-CB65C9BF5B50Q36785795-503439A6-5152-4DA8-BDDE-FD04C6659A41Q36827377-70F840F3-6172-4ECD-B4CB-B0EF10649B89Q37034798-DD180CA7-4EBE-4858-A858-CBC488576C24Q37444204-BBE985CB-6B66-4556-8076-5608E5BE3EACQ37618276-DC986F74-F81B-4618-9C18-AEF22DE34327Q38909755-5426CF9F-28DF-49E6-956A-9307401F23C6Q38936872-C5011FF2-0E90-4B50-A0E7-3FF055765FACQ41925820-74CB13E4-3280-4382-93D2-D1F1A4F82CA1Q52581587-63FDB523-E5A5-46C8-A817-309C4CFC6F37Q53689028-2DC5B6F6-D7D7-4081-BDC2-D5D0CD97FABE
P2860
The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The neutralization sensitivity ...... antibody and envelope variant
@ast
The neutralization sensitivity ...... antibody and envelope variant
@en
type
label
The neutralization sensitivity ...... antibody and envelope variant
@ast
The neutralization sensitivity ...... antibody and envelope variant
@en
prefLabel
The neutralization sensitivity ...... antibody and envelope variant
@ast
The neutralization sensitivity ...... antibody and envelope variant
@en
P2093
P2860
P1433
P1476
The neutralization sensitivity ...... antibody and envelope variant
@en
P2093
Nicholas M Provine
Valerie Cortez
Vrasha Chohan
P2860
P356
10.1016/J.VIROL.2012.02.001
P407
P577
2012-02-25T00:00:00Z